Language selection

Search

VB-GL-3.21.1: Release of unlicensed veterinary biologics manufactured in Canada

This page is part of the Guidance Document Repository (GDR).

Looking for related documents?
Search for related documents in the Guidance Document Repository

On this page

1. Introduction

The Canadian Centre for Veterinary Biologics (CCVB) of the Canadian Food Inspection Agency (CFIA) is responsible for licensing veterinary biologics (VB) in Canada and for regulating their release, and use.

Under certain special circumstances, Canadian veterinarians may apply for the CCVB's permission to obtain a VB that is unlicensed in Canada, for use under their supervision in research or in emergency situations. For product manufactured within Canada, the CCVB issues a Permit to release veterinary biologics, authorizing the transfer of the product from the manufacturer to the veterinarian, and its use by the veterinarian.

The veterinarian who applies for a Permit to release veterinary biologics must provide the CCVB with adequate justification for the use of the unlicensed product in Canada. The CCVB reviews applications to release unlicensed products on a case-by-case basis. Permits to release unlicensed VB are generally issued for specific serials (batches) of product. However, some in vitro diagnostic test kits are not limited by this serial-specific restriction.

1.1 Legal authority

2. Application process

An application for a Permit to release veterinary biologics for research or emergency use must include the following documents. The documentation may be sent by email to the general account cfia.CCVB-CCPBV.acia@inspection.gc.ca, or by mail or fax to the CCVB.

2.1 Information provided by the veterinarian

Note: prior to submitting a Permit to release veterinary biologic application to the CCVB, the veterinarian should confirm that the manufacturer of the unlicensed VB being sought is willing and able to ship the requested product, and prepared to provide the CCVB with the required supporting documents, including product information, samples of labelling, and test results for the serial(s) to be released.

Covering letter from the veterinarian: the application must include a letter, signed by the veterinarian, briefly explaining the rationale for using the unlicensed VB in Canada and accompanied by supporting documentation. The following details should be provided:

2.2 Information provided by the manufacturer

The following documentation may contain confidential business information, and are ordinarily submitted directly to the CCVB by the manufacturer. Submission is required only when requested by the CCVB, as some documents may already be on file from previous permit requests.

Manufacturer's Outline of Production or equivalent document: this document describes the materials and procedures that are used for preparing and testing the product, and serves as a contract between the manufacturer and regulatory agencies.

Summary of test results or equivalent document: when requested by the CCVB, the manufacturer must submit a summary of the test results for the serials (batches) to be released. Manufacturers should submit an official summary of test results, batch release certificate, or equivalent documentation, signed by the "Qualified Person."

Product labels: in some cases, the CCVB may have specific requirements, such as using the statement, "For experimental use only" or "Not for sale in Canada." Refer to VB-GL-3.3: Labelling of veterinary biologics.

Information on the materials of animal origin: the manufacturer must provide a list of all materials of animal origin used in preparing the VB, including the ingredients of the media on which master seeds were grown. For each ingredient, the animal species and tissue/organ from which it was derived, the country of origin of the animal, and the name and address of the supplier should be given (for example, trypsin – porcine – pancreas – Poland – ABC Inc., U.S.). This information helps characterize the product's potential risks for contamination with extraneous micro-organisms and transmissible spongiform encephalopathy agents.

Declaration of Compliance signed by the manufacturer: to obtain sample text for the Declaration of Compliance, refer to Appendix 1 of the VB-GL-3.32: Minimising the risk of introducing transmissible spongiform encephalopathy agents through veterinary biologics.

Note that the CCVB may request additional documents, such as experimental protocols, facility inspection or certification reports, environmental assessments, and summary of suspect adverse reaction reports/vaccine-vigilance data, from the veterinarian or manufacturer, as appropriate. The CCVB additionally reserves the authority to inspect holders of Permits to release veterinary biologics to verify compliance with the Health of Animals Regulations and permit conditions.

3. Additional information

Any further questions from manufacturers and veterinarians, or requests for clarification regarding the regulations and requirements pertaining to the release of unlicensed veterinary biologics, may be directed to the CCVB.

Date modified: